Cenix and Debiopharm collaborate to identify oncology biomarkers

Cenix BioScience and Debiopharm have announced that they will collaborate to identify predictive biomarkers to aid development of preclinical oncology candidates. Cenix, a preclinical contract research provider and specialized in RNAi-, miRNA- and high content-driven pharmacology, will supply its expertise in high throughput screening and high content assays in cultured human cells to support Debiopharm's development of novel therapeutic drugs. …